lunes, 25 de diciembre de 2017

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutat... - PubMed - NCBI

2017 Dec 13. pii: S0302-2838(17)31033-3. doi: 10.1016/j.eururo.2017.12.001. [Epub ahead of print]

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD1, Wang H2, Hahn NM3, Twardowski P4, Pal SK4, Albany C5, Fleming MT6, Starodub A7, Hauke RJ8, Yu M9, Zhao Q9, Sonpavde G10, Donovan MJ11, Patel VG12, Sfakianos JP13, Domingo-Domenech J11, Oh WK12, Akers N14, Losic B14, Gnjatic S12, Schadt EE2, Chen R2, Kim-Schulze S12, Bhardwaj N12, Uzilov AV2.

Author information

Abstract

BACKGROUND:

Chemotherapy may exert immunomodulatory effects, thereby combining favorably with the immune checkpoint blockade. The pharmacodynamic effects of such combinations, and potential predictive biomarkers, remain unexplored.

OBJECTIVE:

To determine the safety, efficacy, and immunomodulatory effects of gemcitabine and cisplatin (GC) plus ipilimumab and explore the impact of somatic DNA damage response gene alterations on antitumor activity.

DESIGN, SETTING, AND PARTICIPANTS:

Multicenter single arm phase 2 study enrolling 36 chemotherapy-naïve patients with metastatic urothelial cancer. Peripheral blood flow cytometry was performed serially on all patients and whole exome sequencing of archival tumor tissue was performed on 28/36 patients.

INTERVENTION:

Two cycles of GC followed by four cycles of GC plus ipilimumab.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

The primary endpoint was 1-yr overall survival (OS). Secondary endpoints included safety, objective response rate, and progression-free survival.

RESULTS AND LIMITATIONS:

Grade ≥3 adverse events occurred in 81% of patients, the majority of which were hematologic. The objective response rate was 69% and 1-yr OS was 61% (lower bound 90% confidence interval: 51%). On exploratory analysis, there were no significant changes in the composition and frequency of circulating immune cells after GC alone. However, there was a significant expansion of circulating CD4 cells with the addition of ipilimumab which correlated with improved survival. The response rate was significantly higher in patients with deleterious somatic DNA damage response mutations (sensitivity=47.6%, specificity=100%, positive predictive value=100%, and negative predictive value=38.9%). Limitations are related to the sample size and single-arm design.

CONCLUSIONS:

GC+ipilimumab did not achieve the primary endpoint of a lower bound of the 90% confidence interval for 1-yr OS of >60%. However, within the context of a small single-arm trial, the results may inform current approaches combining chemotherapy plus immunotherapy from the standpoint of feasibility, appropriate cytotoxic backbones, and potential predictive biomarkers.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01524991.

PATIENT SUMMARY:

Combining chemotherapy and immune checkpoint blockade in patients with metastatic urothelial cancer is feasible. Further studies are needed to refine optimal combinations and evaluate tests that might identify patients most likely to benefit.